<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951677</url>
  </required_header>
  <id_info>
    <org_study_id>HBV002</org_study_id>
    <nct_id>NCT01951677</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine</brief_title>
  <official_title>Phase 1 Randomized, Controlled, Double-blind Study to Compare the Safety and Effectiveness of Hepatitis B Vaccines in Individuals With Renal Impairment, Diabetes Mellitus or Age Greater Than 40 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxine Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flinders Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vaxine Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need for more effective and better-tolerated hepatitis B vaccines for low
      responder high-risk populations including patients with renal impairment and/or diabetes
      mellitus and those aged over 40 years. Several approaches are available to enhance the
      potency of hepatitis B virus vaccines including use of the more highly immunogenic antigens,
      replacing alum with potentially more effective adjuvants, and increasing the dose of vaccine
      antigen. A combination of these strategies is being tested in this study to identify the most
      promising candidate approaches to take forward into advanced clinical development
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvants are a critical ingredient in most vaccines and act by boosting the immune response
      to the target protein (e.g. hepatitis B surface antigen (HBsAg)). Despite considerable
      research, aluminium hydroxide or phosphate compounds (collectively referred to as &quot;alum&quot;)
      remain the dominant adjuvants used in human hepatitis B virus vaccines. There is thus an
      unmet need for new HBV vaccine adjuvants, in particular, for adjuvants capable of boosting
      cell-mediated immunity (this is a particular type of immune response where killer T cells are
      activated that are then able to attack and destroy the infection) as alum, although good at
      stimulating antibodies is very poor at stimulating cell-mediated immunity. Alum, whilst
      generally accepted as safe, can be associated with significant local vaccine reactions and
      this is another reason why newer better-tolerated vaccine adjuvants would be beneficial. This
      study will compare a range of experimental adjuvant formulations to identify those that
      provide the safest and most effective enhancement of T- and B-cell immunity against hepatitis
      B
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Safety as assessed by incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B surface antibody geometric mean titer</measure>
    <time_frame>one-month post each immunization and 10 months post-final immunization</time_frame>
    <description>Geometric mean titer of HBsAg titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell responses</measure>
    <time_frame>7 days and one month post each immunization and 10 months post-final immunization</time_frame>
    <description>HBsAg-specific T cell responses as measured by cytokine enzyme-linked immunospot and carboxyfluorescein diacetate succinimidyl ester T-cell proliferation assay will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>one month post each immunization and 10 months post final immunization</time_frame>
    <description>Seroconversion and seroprotection rates will be compared between groups using titers of antibodies to hepatitis B surface antigen at each major time point</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Exposure to Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>HBsAg + alum adjuvant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBsAg + standard alum adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBsAg + Advax-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBsAg + Advax-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBsAg + Advax-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preS HBsAg + alum adjuvant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preS HBsAg + alum adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preS HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preS HBsAg + Advax-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preS HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preS HBsAg + Advax-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preS HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preS HBsAg + Advax-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose preS HBsAg + alum adjuvant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose preS HBsAg + alum adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose preS HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose preS HBsAg + Advax-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose preS HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose preS HBsAg + Advax-2(TM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose preS HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose preS HBsAg + Advax-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBsAg</intervention_name>
    <description>Standard hepatitis B vaccine antigen</description>
    <arm_group_label>HBsAg + alum adjuvant</arm_group_label>
    <arm_group_label>HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_label>HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_label>HBsAg + Advax-3(TM)</arm_group_label>
    <other_name>hepatitis B vaccine based on hepatitis B surface antigen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PreS HBsAg</intervention_name>
    <description>preS hepatitis B surface antigen</description>
    <arm_group_label>preS HBsAg + alum adjuvant</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + alum adjuvant</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-3(TM)</arm_group_label>
    <other_name>preS hepatitis B surface antigen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Advax-1(TM)</intervention_name>
    <description>Adjuvant formulated with vaccine antigen</description>
    <arm_group_label>HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-1(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-1(TM)</arm_group_label>
    <other_name>Delta inulin adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Advax-2(TM)</intervention_name>
    <description>Adjuvant formulated with vaccine antigen</description>
    <arm_group_label>HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-2(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-2(TM)</arm_group_label>
    <other_name>Supermix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Advax-3(TM)</intervention_name>
    <description>Adjuvant formulated with vaccine antigen</description>
    <arm_group_label>HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_label>preS HBsAg + Advax-3(TM)</arm_group_label>
    <arm_group_label>high dose preS HBsAg + Advax-3(TM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alum</intervention_name>
    <description>Adjuvant formulated with vaccine antigen</description>
    <arm_group_label>HBsAg + alum adjuvant</arm_group_label>
    <arm_group_label>preS HBsAg + alum adjuvant</arm_group_label>
    <arm_group_label>high dose preS HBsAg + alum adjuvant</arm_group_label>
    <other_name>Alhydrogel</other_name>
    <other_name>Aluminium hydroxide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and above

          -  Male or female

          -  Able to provide written informed consent

          -  Willing and able to comply with the protocol for the duration of the study.

          -  Has one or more of

          -  Age 40 years or above

          -  Impaired renal function (creatinine &gt;120 mmol/L or calculated glomerular filtration
             rate &lt;60mls/min)

          -  Diagnosis of diabetes mellitus (any type)

        Exclusion Criteria:

          -  History of prior hepatitis B vaccination

          -  History of serious vaccine allergy if in the opinion of the Investigator this
             represents a contraindication to hepatitis B vaccination

          -  Women of childbearing potential unless using a reliable and appropriate contraceptive
             method, specifically oral contraceptive pill, intrauterine device or mechanical
             barrier device.

          -  Pregnant or lactating women.

          -  History of systemic autoimmune disease including Wegener's granulomatosis, systemic
             lupus erythematosus, Guillain-Barre, scleroderma or multiple sclerosis.

          -  Participation in another clinical trial with an investigational agent within 28 days
             of the scheduled date of first immunization.

          -  Any other serious medical, social or mental condition that, in the opinion of the
             investigator, would be detrimental to the subjects or the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Barbara, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis B virus</keyword>
  <keyword>vaccine</keyword>
  <keyword>adjuvant</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently no plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

